Abstract: AIM: To study the inhibitory effect of Xihuang Pill on H22 tumor-bearing mice and its related mechanism.  METHODS: The H22 tumor-bearing mouse model was used to analyze the inhibitory effect of Xihuang Pill on tumor; the contents of CD3+, CD4+, and CD8+ cells in blood were determined by flow cytometry; the contents of related factors were determined by enzyme-linked immunosorbent assay. Network pharmacology predicted the relevant pathways of its inhibition of liver cancer, and verified the key protein targets by Western Blot. RESULTS: Xihuang pill administration group could reduce the tumor weight of H22 tumor-bearing mice (P<0.05); increase the thymus index and spleen index (P<0.05), and increase the level of CD4+/CD8+ (P<0.05); The levels of IL-2 and IFN-γ decreased the levels of IL-6 and IL-10 (P<0.05). 77 important active ingredients and 28 core targets were obtained through network pharmacology screening. Western blot verification showed that Xihuang pills had a significant regulatory effect on the key protein targets of PI3K-Akt-MMP9 pathway. CONCLUSION: Xihuang pill has the effect of inhibiting the transplanted tumor of liver cancer and correcting the immune disorder of the tumor-bearing mice.

Key words: Xihuang pill, H22 liver cancer cell, network pharmacology, integrated regulation